Aloe vera is one of the most significant therapeutical plant species that belongs to the family Liliaceae. Aloe vera is composed of a high amount of water, with the remainder being dry matter. The dry matter contains a lot of bioactive compounds like carbohydrates, fats, and enzymes, with various therapeutic and antimicrobial properties. It can enhance the proliferation of cells and prevent cell damage by anti-oxidative properties (stimulating the secretion of superoxide dismutase and peroxidase). Human skin is colonized by microbes like fungi (Candida albicans), bacteria (Propionibacterium acnes, Staphylococcus aureus), and mites. These commensals are responsible for skin characteristics such as acidic pH, the pungent smell of sweat, etc. Human fetuses lack skin microbiota, and their skin is colonized after birth. Commensals present on the skin have a crucial role in training the human immune system against other pathogenic microbes. Propionibacterium acnes act as an opportunistic pathogen when the balance between the commensals is disturbed. We also emphasize the recent progress in identifying the aloe metabolite biosynthesis pathways and the associated enzyme machinery. The hyperproliferation of Propionibacterium acnes causes acne, and acemannan plays a significant role in its cure. Hence, we need to consider a new treatment approach based on the root cause of this dysbiosis.
Today, researchers have already made great progress in finding drug-based clinical solutions against microbial infections. It has become an essential part of a healthy human lifestyle. High antibiotic consumption has accelerated antibiotic resistance in microbial species (multi-drug-resistant microbial strains, like Staphylococcus aureus and Mycobacterium tuberculosis, have already been reported). Loss of microflora is also associated with the heavy and unnecessary use of drugs. This review presents bacteriophage as an alternative to antibiotics. The supporting bacteriophage characteristics include bacteriophage lytic mode of replication, specificity towards its host, bacteriophage mass production, and bacteriophage genetic modification (BRED and CRISPR) to make it capable of degrading microbial biofilm. The author has also tried to inculcate previous work that has already been done with bacteriophages for some clinical therapies. Potential administration routes (oral, intravenous, and intraoperative) used in clinical therapies are discussed.